Business
Novo Nordisk Shares Drop 10% Following Disappointing Weight Loss Trial Results
Novo Nordisk's new obesity drug CagriSema demonstrated 23% weight loss but failed to meet the primary endpoint in a key REDEFINE 4 trial, leading to a significant share price decline.